47 results
424B3
CHRS
Coherus Biosciences Inc
26 Jul 23
Prospectus supplement
4:59pm
, as applicable (including each company’s ability to achieve strategic goals, objectives and targets over applicable periods), industry performance
S-4/A
CHRS
Coherus Biosciences Inc
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
and uncertainties relating to Coherus’ or Surface’s business, as applicable (including each company’s ability to achieve strategic goals, objectives
S-4
CHRS
Coherus Biosciences Inc
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
to achieve strategic goals, objectives and targets over applicable periods), industry performance, general business and economic conditions.
The COVID-19
425
v59 iuwezw2glgizs
16 Jun 23
Business combination disclosure
5:17pm
425
0qn4c7xidymu mt
16 Jun 23
Business combination disclosure
5:16pm
425
3qjbngrani oj
16 Jun 23
Business combination disclosure
5:14pm
425
72f9nchfyn1dex
16 Jun 23
Business combination disclosure
5:14pm
425
c8gvqjyrqdej
16 Jun 23
Business combination disclosure
5:12pm
425
wq89xukhcu9 el6xo
16 Jun 23
Business combination disclosure
5:11pm
425
on3w6
16 Jun 23
Business combination disclosure
8:08am
425
o8o3jmrtliun gxe
16 Jun 23
Business combination disclosure
7:09am
8-K
EX-99.1
qimt980g9hsrqyl5ldra
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
no5ekyr6kq5ucn9wc
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-99.1
e0kcbj
8 Nov 21
Coherus BioSciences Reports Third Quarter 2021 Results
4:06pm